Single-Cell Sequencing Market Size to Reach USD 9.83 Billion by 2035 | SNS Insider

Single-cell sequencing markets are forecast to grow strongly: the U.S. rises from $1.05B (2025) to $4.07B by 2035, and Europe from $1.63B to $6.25B. Growth is attributed to expanding genomics research, precision medicine adoption, and increased next-generation sequencing use. Overall, this points to a favorable long-run demand backdrop for the sector.

Analysis

This is a multi-year TAM story, not a near-term catalyst. The economic value should accrue first to the few platforms that monetize installed base through recurring consumables and workflow lock-in, while generic sequencing hardware is at risk of becoming a feature, not the profit pool. In other words, the market growth can be real while equity value migrates toward firms with the strongest reagent pull-through and sample-prep attachment rates.

The second-order winner is likely the broader genomics toolchain: sample prep, microfluidics, bioinformatics, and cloud compute/storage linked to larger data outputs. That creates spillover for software and infrastructure suppliers more than for pure instrument OEMs, because single-cell adoption increases data volume faster than assay count. The loser set is the lower-end bulk transcriptomics and legacy workflow vendors that face substitution pressure as researchers standardize on single-cell readouts for discovery work.

The main risk is that projected market CAGR overstates profit pool growth: pricing tends to compress as protocols commoditize, academic budgets remain cyclical, and pharma procurement requires proof of reproducibility before scaling. Near term, this likely shows up as lumpy instrument bookings, but the real falsifier is 1-3 quarter consumables underperformance or management commentary that utilization is below expectations. If NIH/funding or biotech capex weakens, the category can still look structurally attractive while public comps de-rate.

Consensus may be underestimating how much of the growth becomes captured by adjacent incumbents rather than the pure-play single-cell names. The better trade is exposure to the ecosystem with diversification across sequencing, sample prep, and data tools; the worse trade is paying up for category growth alone without evidence of margin durability. If adoption inflects, the market should reward recurring revenue models first and only then the broader genomics basket.

Key Decisions for Investors

• No immediate outright trade on the market-size projection alone; treat this as a long-duration watch item until next-quarter consumables growth or instrument bookings validate adoption.
• If seeking direct exposure, prefer a starter long in TXG on a pullback, but only if valuation is below the market's implied growth rate; otherwise the multiple can compress faster than TAM expands.
• Pair idea: long TXG / short a broader genomics ETF or basket proxy such as IBB on any strength if you want to isolate single-cell share gains from a crowded life-science beta trade.
• Watch ILMN and TMO as secondary beneficiaries; if they begin highlighting single-cell workflow attach rates, that is a better confirmation signal than the market forecast itself.
• Falsifier: two consecutive quarters of soft consumables revenue or management guidance that single-cell demand is being delayed by academic/pharma budget tightening.